Follow
Stefania Crucitta
Stefania Crucitta
Verified email at med.unipi.it
Title
Cited by
Cited by
Year
The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients
M Del Re, E Biasco, S Crucitta, L Derosa, E Rofi, C Orlandini, M Miccoli, ...
European urology 71 (4), 680-687, 2017
2612017
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
M Del Re, R Marconcini, G Pasquini, E Rofi, C Vivaldi, F Bloise, ...
British journal of cancer 118 (6), 820-824, 2018
2242018
Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment
E Arrigoni, M Del Re, S Galimberti, G Restante, E Rofi, S Crucitta, ...
Stem cells translational medicine 7 (3), 305-314, 2018
862018
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
M Del Re, S Crucitta, G Gianfilippo, A Passaro, I Petrini, G Restante, ...
International journal of molecular sciences 20 (16), 3951, 2019
792019
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients
M Del Re, I Bertolini, S Crucitta, L Fontanelli, E Rofi, C De Angelis, ...
Breast Cancer Research and Treatment 178, 57-62, 2019
762019
The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate/prednisone and enzalutamide
M Del Re, S Fogli, L Derosa, F Massari, P De Souza, S Crucitta, ...
Cancer treatment reviews 55, 71-82, 2017
672017
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs
S Fogli, C Porta, M Del Re, S Crucitta, G Gianfilippo, R Danesi, BI Rini, ...
Cancer Treatment Reviews 84, 101966, 2020
522020
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
M Del Re, E Rofi, G Restante, S Crucitta, E Arrigoni, S Fogli, M Di Maio, ...
Oncotarget 9 (5), 6630, 2018
502018
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
M Del Re, V Citi, S Crucitta, E Rofi, F Belcari, R van Schaik, R Danesi
Pharmacological Research 107, 398-406, 2016
502016
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
M Del Re, S Cinieri, A Michelucci, S Salvadori, F Loupakis, M Schirripa, ...
The pharmacogenomics journal 19 (6), 556-563, 2019
452019
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC
P Bordi, M Del Re, R Minari, E Rofi, S Buti, G Restante, A Squadrilli, ...
Lung Cancer 131, 78-85, 2019
452019
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
M Del Re, P Bordi, E Rofi, G Restante, S Valleggi, R Minari, S Crucitta, ...
British journal of cancer 119 (10), 1252-1258, 2018
402018
Concise review: resistance to tyrosine kinase inhibitors in non-small cell lung cancer: the role of cancer stem cells
M Del Re, E Arrigoni, G Restante, A Passaro, E Rofi, S Crucitta, ...
Stem Cells 36 (5), 633-640, 2018
382018
Incidence of T790M in patients with NSCLC progressed to gefitinib, erlotinib, and afatinib: a study on circulating cell-free DNA
M Del Re, I Petrini, F Mazzoni, S Valleggi, G Gianfilippo, D Pozzessere, ...
Clinical Lung Cancer 21 (3), 232-237, 2020
372020
Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients
F Martignano, U Munagala, S Crucitta, A Mingrino, R Semeraro, M Del Re, ...
Molecular cancer 20, 1-6, 2021
362021
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
M Del Re, V Conteduca, S Crucitta, G Gurioli, C Casadei, G Restante, ...
Prostate cancer and prostatic diseases 24 (2), 524-531, 2021
342021
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients
M Del Re, S Crucitta, G Lorenzini, C De Angelis, L Diodati, D Cavallero, ...
Pharmacological Research 163, 105241, 2021
322021
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
M Del Re, C Omarini, L Diodati, M Palleschi, I Meattini, S Crucitta, ...
ESMO open 6 (5), 100231, 2021
312021
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
M Del Re, F Cucchiara, E Rofi, L Fontanelli, I Petrini, N Gri, G Pasquini, ...
Cancer Immunology, Immunotherapy 70, 1667-1678, 2021
302021
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer
E Rofi, C Vivaldi, M Del Re, E Arrigoni, S Crucitta, N Funel, S Fogli, ...
Pharmacogenomics 20 (01), 49-68, 2019
302019
The system can't perform the operation now. Try again later.
Articles 1–20